

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal (MTA)

Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of pseudomonas lung infection in cystic fibrosis

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

Version of matrix of consultees and commentators reviewed:				
Provisional matrix of consultees and commentators sent for consultation				
Summary of comments, action taken, and justification of action:				
	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
1.	Add British Paediatric Respiratory Society	British Thoracic Society	Added	This organisation has an area of interest closely related to this appraisal topic and meets the selection criteria to participate in this appraisal. British Paediatric Respiratory Society has been added to the matrix of consultees and commentators under 'professional groups'.
2.	Add Association of Chartered Physiotherapists in Respiratory Care	Novartis Pharmaceuticals UK	Added	This organisation has an area of interest closely related to this appraisal topic and meets the selection criteria to participate in this appraisal. Association of Chartered Physiotherapists in Respiratory Care has been added to the matrix of consultees and commentators under 'professional groups'.

Appendix D

3.	Add Chartered Society of Physiotherapy	Novartis Pharmaceuticals UK	Added	This organisation has an area of interest closely related to this appraisal topic and meets the selection criteria to participate in this appraisal. Chartered Society of Physiotherapy has been added to the matrix of consultees and commentators under 'professional groups'.
4.	Add Association of Chartered Physiotherapists in Cystic Fibrosis	Novartis Pharmaceuticals UK	Not included	Association of Chartered Physiotherapists in Cystic Fibrosis are a sub group of Chartered Society of Physiotherapy who are included on the matrix so have therefore have not been added.
5.	Add Clinical Trials Network of the European Cystic Fibrosis Society.	Royal College of Pathologists	Not Included	There are no UK based groups affiliated with this organisation, therefore Clinical Trials Network of the European Cystic Fibrosis Society therefore they do not meet the inclusion criteria and have not been added to the matrix.
6.	Remove Forest Laboratories UK (colistimethate sodium powder for inhalation) This has no MA and therefore should be removed. This document needs to include colistimethate sodium 1 to 2 million IU in solution manufactured by Forest Laboratories UK.	Profile Pharma	Noted	Comment noted and the comparator list has been updated following initial draft scope consultation and scoping workshop.
7.	Remove Novartis. This has no MA and therefore should be removed. This document needs to include TOBI 300mg/5mL in solution. Manufactured by Novartis	Profile Pharma	Noted	Comment noted and the comparator list has been updated following initial draft scope consultation and scoping workshop.
8.	Add Profile Pharma	Profile Pharma	Added	Comment noted and the comparator list has been updated following initial draft scope consultation and scoping workshop.
9.	Add Gilead. This is a recently licensed inhaled antibiotic for the treatment of pseudomonas aeruginosa in cystic fibrosis	Profile Pharma	Added	Comment noted and the comparator list has been updated following initial draft scope consultation and scoping workshop.